Table 3. Summary of belantamab mafodotin... | American Society of Hematology

Table 3.

Summary of belantamab mafodotin real-world studies

Author	Country/setting	Number of patients	EAP	ORR (%)	PFS (mo)	OS (mo)	Ocular toxicity
Alegre et al¹²	Spain, multicenter	33	Yes	42.2	3	13	Keratopathy (51.5%) Patient-reported vision-related symptoms (45.5%)
Atieh et al¹³	Kansas, US single center	35	Partly	43	4.9	10.7	86%
de la Rubia et al¹⁴	Spain, multicenter	156	Yes	40	3.6	11	87.9% grade ≥3 was 33.7%
Iula et al¹⁵	Italy, 4 hematology centers	28	No	40	3	8	Keratopathy 32%
Ntanasis-Stathopoulos et al¹⁷	Greece	27	Yes	52	2	16	Keratopathy 33%
Mohan et al¹⁶	Wisconsin and Arkansas, 2 US academic institutions	56	No	44.6	3.6	10	71.4% Grade 3 keratopathy 54%
Roussel et al¹⁸	France, multicenter	184	Yes	32.7	2.4	8.8	56% Grade 3 keratopathy 27%
Shragai et al¹⁹	Israel, multicenter	106	Yes	45.5	4.7	14.5	68.4% Grade 3 keratopathy 40.5%
Talbot et al²⁰	France, multicenter	104	Yes	38.1	3.5	9.3	37%
Vaxman et al²¹	One US academic institution, 3 centers	36	No	33	2	6.5	44%

Author	Country/setting	Number of patients	EAP	ORR (%)	PFS (mo)	OS (mo)	Ocular toxicity
Alegre et al¹²	Spain, multicenter	33	Yes	42.2	3	13	Keratopathy (51.5%) Patient-reported vision-related symptoms (45.5%)
Atieh et al¹³	Kansas, US single center	35	Partly	43	4.9	10.7	86%
de la Rubia et al¹⁴	Spain, multicenter	156	Yes	40	3.6	11	87.9% grade ≥3 was 33.7%
Iula et al¹⁵	Italy, 4 hematology centers	28	No	40	3	8	Keratopathy 32%
Ntanasis-Stathopoulos et al¹⁷	Greece	27	Yes	52	2	16	Keratopathy 33%
Mohan et al¹⁶	Wisconsin and Arkansas, 2 US academic institutions	56	No	44.6	3.6	10	71.4% Grade 3 keratopathy 54%
Roussel et al¹⁸	France, multicenter	184	Yes	32.7	2.4	8.8	56% Grade 3 keratopathy 27%
Shragai et al¹⁹	Israel, multicenter	106	Yes	45.5	4.7	14.5	68.4% Grade 3 keratopathy 40.5%
Talbot et al²⁰	France, multicenter	104	Yes	38.1	3.5	9.3	37%
Vaxman et al²¹	One US academic institution, 3 centers	36	No	33	2	6.5	44%

EAP, expanded access program.